News | January 23, 2014

Three-Year Data Shows Stent Treatment Of Blocked Leg Arteries Lasts, Helps Patients Maintain Improved Quality Of Life

Peripheral artery disease PAD treatments Stents Clinical Trial Study STROLL

January 24, 2014 — Peripheral artery disease (PAD) sufferers maintain improved quality of life, including being able to walk farther, three years after being treated with stents to open their blocked leg arteries, according to STROLL trial results presented at the 26th annual International Symposium on Endovascular Therapy (ISET).
 
Leg arteries remained open in nearly three-quarters of patients who were treated with nickel titanium (nitinol) stents, and they continued to enjoy improved quality of life, according to the study.
 
In the study, self-expanding stents were placed in blockages in the superficial femoral artery of 250 patients. Blockages averaged 7.7 cm, and 23.6 percent of them were completely closed. Three years after treatment, 72.7 percent of arteries remained opened in 209 patients. 3.6 percent of stents had fractured, but all were the least-severe form and caused no problems while continuing to keep arteries open. Blood pressure in the legs remained significantly improved, with almost no change over three years. Further, patients maintained their improved health-related quality of life as measured by several factors, including symptoms and walking distance and speed.
 
STROLL (S.M.A.R.T. Nitinol Self-Expanding Stent in the TReatment of Obstructive SuperficiaL FemoraL Artery Disease) is a multicenter, nonrandomized, single-arm prospective trial studying the safety and efficacy of the S.M.A.R.T. stent. Patients were treated at one of 39 centers.
 
Find out more: www.iset.ge

Related Content

News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
News | Cardiovascular Clinical Studies

Jan. 13, — A new cohort study among 103,642 adults found that current use of cigars was associated with increased risk ...

Home January 14, 2025
Home
News | Cardiovascular Clinical Studies

Nov. 22, 2024 — BridgeBio Pharma, Inc. recently announced that the U.S. Food and Drug Administration (FDA) approved ...

Home November 25, 2024
Home
News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
Subscribe Now